KIT and melanoma: Given these clinical trial results demonstrating clinical benefit of KIT inhibitors, the National Comprehensive Cancer Network (NCCN) guidelines recommended KIT‐targeted therapy as one of the second‐line systemic therapies for metastatic or unresectable melanoma with active KIT mutations.